Keywords: diosynth, extends, deal, pdl, retavase, biotechnology, division
Diosynth extends deal with PDL on Retavase
Article | 12 February 2007
Diosynth Biotechnology, a US division of Dutch group Organon, signed an extension of its exclusive agreement with USA-based PDL BioPharma ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
